Bvf Inc
Bvf Inc reported 47 holdings worth US$3.04B as of Sep 30, 2026 (Form 13F)
As of Sep 30, 2026 · Filed Nov 16, 2026
Bvf Inc reported 47 holdings worth US$3.04B as of Sep 30, 2026. Largest: Revolution Medicines, Inc., Kymera Therapeutics, Inc. and Xencor, Inc. Filed Nov 16, 2026 (Form 13F).
- Holdings
- 47
- Value as reported
- US$3.04B
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Revolution Medicines, Inc. | 2.46M | US$505M | 16.6% |
| Kymera Therapeutics, Inc. | 3.87M | US$433M | 14.2% |
| Xencor, Inc. | 6.23M | US$155M | 5.1% |
| Nektar Therapeutics | 2.13M | US$129M | 4.2% |
| Stoke Therapeutics, Inc. | 3.61M | US$93.8M | 3.1% |
| Tyra Biosciences, Inc. | 4.22M | US$92.2M | 3.0% |
| Zymeworks Inc. | 3.46M | US$91.8M | 3.0% |
| Cullinan Therapeutics, Inc. | 5.75M | US$88.3M | 2.9% |
| Structure Therapeutics, Inc. | 2.69M | US$84.2M | 2.8% |
| Palvella Therapeutics, Inc. | 607K | US$83.7M | 2.8% |
| Kura Oncology, Inc. | 6.69M | US$71.7M | 2.4% |
| Monte Rosa Therapeutics, Inc. | 4.28M | US$51M | 1.7% |
| Olema Pharmaceuticals, Inc. | 5.3M | US$45.8M | 1.5% |
| Crescent Biopharma, Inc. | 3.09M | US$45.1M | 1.5% |
| 4D Molecular Therapeutics, Inc. | 2.88M | US$41.2M | 1.4% |
| Immunocore Holdings plc | 1.23M | US$37.3M | 1.2% |
| Annexon, Inc. | 8.28M | US$35M | 1.2% |
| Mirum Pharmaceuticals, Inc. | 407K | US$34.8M | 1.1% |
| Sagimet Biosciences Inc. - Series A | 3.5M | US$34.6M | 1.1% |
| Pyxis Oncology, Inc. | 11.8M | US$27.6M | 0.91% |
| Absci Corporation | 2.36M | US$25.4M | 0.84% |
| Invivyd, Inc. | 28.2M | US$24.5M | 0.81% |
| Anteris Technologies Global Corp. | 3M | US$23.3M | 0.77% |
| Foghorn Therapeutics Inc. | 5.84M | US$20.9M | 0.69% |
| Sutro Biopharma, Inc. | 1.25M | US$20.2M | 0.66% |
| Q32 Bio Inc. | 2.35M | US$19.4M | 0.64% |
| Alector, Inc. | 10M | US$18.6M | 0.61% |
| Eledon Pharmaceuticals, Inc. | 6.29M | US$15.9M | 0.52% |
| Disc Medicine, Inc. | 233K | US$15.3M | 0.50% |
| Avalo Therapeutics, Inc. | 907K | US$13.9M | 0.46% |
| OnKure Therapeutics, Inc. | 4.05M | US$11M | 0.36% |
| Immunic, Inc. | 765K | US$7.12M | 0.23% |
| TCGX Acquisition Corp. | 500K | US$6.25M | 0.21% |
| Research Alliance Corporation IV | 500K | US$5.92M | 0.19% |
| Research Alliance Corporation III | 500K | US$5.36M | 0.18% |
| Molecular Partners AG | 1.35M | US$5.19M | 0.17% |
| ImageneBio, Inc. | 1.11M | US$5.08M | 0.17% |
| X4 Pharmaceuticals, Inc. | 1.58M | US$4.57M | 0.15% |
| Inventiva SA | 686K | US$2.53M | 0.08% |
| TScan Therapeutics, Inc. | 5.56M | US$1.75M | 0.06% |
| Tenax Therapeutics, Inc. | 25,000 | US$47,250 | <0.01% |
| XOMA Royalty Corporation | 0 | US$0 | 0.00% |
Source
Download original · View original at SEC
Related